Document is current
Any future updates will be listed below
-
Authors
Chen, Ming
Chen, Runzhe
Jin, Ying
Li, Jun
Hu, Xin
Zhang, Jiexin https://orcid.org/0000-0001-9526-6730
Fujimoto, Junya
Hubert, Shawna M. https://orcid.org/0000-0002-7907-9609
Gay, Carl M. https://orcid.org/0000-0002-4907-0718
Zhu, Bo
Tian, Yanhua
McGranahan, Nicholas https://orcid.org/0000-0001-9537-4045
Lee, Won-Chul
George, Julie https://orcid.org/0000-0002-4272-3683
Hu, Xiao
Chen, Yamei
Wu, Meijuan
Behrens, Carmen
Chow, Chi-Wan
Pham, Hoa H. N. https://orcid.org/0000-0002-0998-4486
Fukuoka, Junya
Wu, Jia https://orcid.org/0000-0001-8392-8338
Parra, Edwin Roger https://orcid.org/0000-0001-9068-1636
Little, Latasha D.
Gumbs, Curtis
Song, Xingzhi
Wu, Chang-Jiun https://orcid.org/0000-0001-8350-6397
Diao, Lixia https://orcid.org/0000-0001-6995-4492
Wang, Qi https://orcid.org/0000-0003-0858-9393
Cardnell, Robert
Zhang, Jianhua https://orcid.org/0000-0001-5412-9860
Wang, Jing https://orcid.org/0000-0002-5398-0802
Le, Xiuning https://orcid.org/0000-0002-8554-1185
Gibbons, Don L. https://orcid.org/0000-0003-2362-3094
Heymach, John V. https://orcid.org/0000-0001-9068-8942
Jack Lee, J. https://orcid.org/0000-0001-5469-9214
William, William N. Jr
Cheng, Chao https://orcid.org/0000-0002-5002-3417
Glisson, Bonnie
Wistuba, Ignacio
Andrew Futreal, P. https://orcid.org/0000-0001-8663-2671
Thomas, Roman K.
Reuben, Alexandre https://orcid.org/0000-0003-4510-0382
Byers, Lauren A. https://orcid.org/0000-0002-0780-2677
Zhang, Jianjun https://orcid.org/0000-0001-7872-3477
- License Information
-
More Information
Article History
Received: 10 June 2020
Accepted: 25 October 2021
First Online: 17 November 2021
Competing interests
: L.A.B. serves on advisory committees for AstraZeneca, AbbVie, GenMab, BergenBio, Pharma Mar SA, Sierra Oncology, Merck, Bristol Myers Squibb, Genentech, and Pfizer, and has research support from AbbVie, AstraZeneca, GenMab, Sierra Oncology, and Tolero Pharmaceuticals. I.W. reports grants and personal fees from Genentech/Roche, Bayer, Bristol-Myers Squibb, AstraZeneca/Medimmune, Pfizer, HTG Molecular, Merck, and Guardant Health; personal fees from GlaxoSmithKline and MSD; grants from Oncoplex, DepArray, Adaptive, Adaptimmune, EMD Serono, Takeda, Amgen, Karus, Johnson & Johnson, Iovance, 4D, Novartis, Oncocyte, and Akoya. J.Z. reports research funding from Merck, Johnson and Johnson, and consultant fees from BMS, Johnson and Johnson, AstraZeneca, Geneplus, OrigMed, and Innovent outside the submitted work. J.V.H. reports honorariums from AstraZeneca, Boehringer-Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Guardant Health, Foundation medicine, Hengrui Therapeutics, Eli Lilly, Novartis, Spectrum, EMD Serono, Sanofi, Takeda, Mirati Therapeutics, BMS, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, EMD Serono, Pneuma Respiratory, Kairos Venture Investments, Roche, and Leads Biolabs. A.R. serves on the Scientific Advisory Board and has received honoraria from Adaptive Biotechnologies. X.L. receives consulting/advisory fees from EMD Serono (Merck KGaA), AstraZeneca, Spectrum Pharmaceutics, Novartis, Eli Lilly, Boehringer Ingelheim, Janssen, Hengrui Therapeutics, and AbbVie, and research funding to the institute from Eli Lilly and Boehringer Ingelheim. R.K.T. is a founder of NEO New Oncology, acquired by Siemens Healthcare, a founder of PearlRiver Bio, acquired by Centessa, a founder of Epiphanes Inc. and a shareholder of Centessa and Epiphanes. R.K.T. has received honoraria from PearlRiver Bio. The other authors declare no competing interests.
